News
VTYX
--
0.00%
--
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
Watch for these 3 catalysts and consider these 6 stocks.
marketwatch.com · 1d ago
Ventyx Biosciences GAAP EPS of -$0.45 beats by $0.07
Ventyx Biosciences press release (NASDAQ:VTYX): Q1 GAAP EPS of -$0.45 beats by $0.07. Cash and cash equivalents of $273.14M
Seekingalpha · 05/12 20:30
BRIEF-Ventyx Biosciences Reports Q1 2022 Results
reuters.com · 05/12 20:03
Ventyx Biosciences Reports Narrower Than Expected Q1 Loss
MT Newswires · 05/12 17:15
Ventyx Biosciences initiated at outperform at Credit Suisse on immune system candidates
Credit Suisse has initiated Ventyx Biosciences (NASDAQ:VTYX) with an outperform rating citing the company's Tyrosine kinase 2 (TYK2) inhibitor VTX958 as positioned to become the best in class. The firm
Seekingalpha · 05/09 16:30
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades
Benzinga · 05/09 14:07
BRIEF-Ventyx Biosciences Announces Appointment Of William Sandborn, MD, As President And Chief Medical Officer
reuters.com · 05/09 12:31
--Credit Suisse Initiates Ventyx Biosciences at Outperform with $53 Price Target
MT Newswires · 05/09 11:58
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unm...
GlobeNewswire · 05/05 20:05
Thomas Steyer’s Farallon Capital is Buying These 10 Stocks
In this article, we discuss 10 stocks that Thomas Steyer’s Farallon Capital is buying. If you want to see some more of his latest stock picks, check out Thomas Steyer’s Farallon Capital is Buying These 5 Stocks. Thomas Steyer is an American investor, entre...
Insider Monkey · 04/20 14:16
10 Little-Known Stocks Billionaire Dan Loeb is Buying
In this article, we discuss 10 little known stocks billionaire Dan Loeb is buying. If you want to see more unknown stocks in his portfolio, click 5 Little-Known Stocks Billionaire Dan Loeb is Buying. Dan Loeb is an American activist investor who founded th...
Insider Monkey · 04/20 13:43
Catalyst watch: Tesla earnings, Lululemon investor event, Bitcoin mining SPAC watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 04/15 17:00
Canaccord Genuity Initiates Ventyx Biosciences at Buy With $30 Price Target
MT Newswires · 03/31 08:23
BRIEF-Ventyx Biosciences Reports Full Year 2021 Financial Results
reuters.com · 03/23 12:42
Ventyx Biosciences Full-Year 2021 Loss Narrows
MT Newswires · 03/23 08:51
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory disea...
GlobeNewswire · 03/07 13:00
Oppenheimer Says These 2 ‘Strong Buy’ Stocks Could Double This Year
The markets were already on shaky ground in 2022’s opening period, as the prospect of inflation and higher interest rates loomed large. But the volume has been turned up significantly now there is a full-scale war to contend with following Putin’s invasion...
TipRanks · 03/03 18:10
--Oppenheimer Initiates Coverage on Ventyx Biosciences With Outperform Rating, $30 Price Target
MT Newswires · 02/01 10:08
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 01/21 15:01
Ventyx Biosciences Announces First Patient Dosed In Phase 2 Clinical Trial Of VTX002 For Treatment Of Moderate-To-Severe Ulcerative Colitis
Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory
Benzinga · 12/06/2021 13:02
Webull provides a variety of real-time VTYX stock news. You can receive the latest news about Ventyx Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The Company is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.